Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3268202 | Endocrinology and Metabolism Clinics of North America | 2009 | 31 Pages |
Abstract
Low-density lipoprotein cholesterol (LDL-C) level currently is used as the major determinant of lipid- and lipoprotein-associated risk for ischemic cardiovascular disease, and varying levels have become the standard goals of lipid-altering treatment. The predictive value of the LDL-C cholesterol level, however, often is less than that provided by other variables such as non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (apoB), and the number of LDL particles measured by nuclear magnetic resonance spectroscopy. This article reviews studies that compare these different lipoprotein variables, describes advanced methodologies of lipoprotein testing, and suggests goals of treatment and clinical situations in which these tests might be ordered.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Joe F. MD, PhD, Donald A. MD, MPH,